اخبار بازار

0 0 0

منبع: Zacks Investment Research خبرگزاری

یک ماه پیش

سهام اهمیت متوسط

FUJIY Q1 Earnings Fall Y/Y on Bio CDMO Costs, Revenues Rise

FUJIFILM's Q1 revenue hit a record yen 826.5 billion, but earnings fell 30% as Bio CDMO costs and restructuring weighed on profitability.

نمادهای مرتبط 1

F FUJIY FUJIY

منبع: Zacks Investment Research

0 0 0

منبع: CNBC خبرگزاری

یک ماه پیش

سهام اهمیت متوسط

Shares of this digital medical platform were up more than 100% at one point. Here's what's driving it

Doximity had a solid first quarter and raised its full year revenue guidance. But AI search isn't baked into these forecasts, analysts believe, and it's bringing in 10 times the revenue it costs to run, the CEO revealed on the conference call.

نمادهای مرتبط 1

D DOCS DOCS

منبع: CNBC

0 0 0

منبع: Zacks Investment Research خبرگزاری

یک ماه پیش

سهام اهمیت متوسط

Construction Partners (ROAD) Q3 Earnings and Revenues Surpass Estimates

Construction Partners (ROAD) came out with quarterly earnings of $1.08 per share, beating the Zacks Consensus Estimate of $1.06 per share. This compares to earnings of $0.81 per share a year ago.

نمادهای مرتبط 1

R ROAD ROAD

منبع: Zacks Investment Research

0 0 0

منبع: Zacks Investment Research خبرگزاری

یک ماه پیش

سهام اهمیت متوسط

Treace Medical Concepts (TMCI) Reports Q2 Loss, Tops Revenue Estimates

Treace Medical Concepts (TMCI) came out with a quarterly loss of $0.24 per share versus the Zacks Consensus Estimate of a loss of $0.3. This compares to a loss of $0.28 per share a year ago.

نمادهای مرتبط 1

T TMCI TMCI

منبع: Zacks Investment Research

0 0 0

منبع: Zacks Investment Research خبرگزاری

یک ماه پیش

سهام اهمیت متوسط

Rapid Micro Biosystems, Inc. (RPID) Reports Q2 Loss, Tops Revenue Estimates

Rapid Micro Biosystems, Inc. (RPID) came out with a quarterly loss of $0.27 per share versus the Zacks Consensus Estimate of a loss of $0.26. This compares to a loss of $0.27 per share a year ago.

نمادهای مرتبط 1

R RPID RPID

منبع: Zacks Investment Research

0 0 0

منبع: Zacks Investment Research خبرگزاری

یک ماه پیش

سهام اهمیت متوسط

Starz Entertainment Corp. (STRZ) Reports Q2 Loss, Tops Revenue Estimates

Starz Entertainment Corp. (STRZ) came out with a quarterly loss of $1.26 per share versus the Zacks Consensus Estimate of a loss of $0.27. This compares to a loss of $2.23 per share a year ago.

نمادهای مرتبط 1

S STRZ STRZ

منبع: Zacks Investment Research

0 0 0

منبع: Zacks Investment Research خبرگزاری

یک ماه پیش

سهام اهمیت متوسط

ARKO Corp. (ARKO) Q2 Earnings Lag Estimates

ARKO Corp. (ARKO) came out with quarterly earnings of $0.04 per share, missing the Zacks Consensus Estimate of $0.15 per share. This compares to earnings of $0.16 per share a year ago.

نمادهای مرتبط 1

A ARKO ARKO

منبع: Zacks Investment Research

0 0 0

منبع: Zacks Investment Research خبرگزاری

یک ماه پیش

سهام اهمیت متوسط

Gyre Therapeutics, Inc. (GYRE) Reports Q2 Loss, Beats Revenue Estimates

Gyre Therapeutics, Inc. (GYRE) came out with a quarterly loss of $0.12 per share versus the Zacks Consensus Estimate of a loss of $0.08. This compares to earnings of $0.02 per share a year ago.

نمادهای مرتبط 1

G GYRE GYRE

منبع: Zacks Investment Research

0 0 0

منبع: Zacks Investment Research خبرگزاری

یک ماه پیش

سهام اهمیت متوسط

Johnson Outdoor (JOUT) Q3 Earnings and Revenues Top Estimates

Johnson Outdoor (JOUT) came out with quarterly earnings of $1.42 per share, beating the Zacks Consensus Estimate of $0.68 per share. This compares to earnings of $0.75 per share a year ago.

نمادهای مرتبط 1

J JOUT JOUT

منبع: Zacks Investment Research

0 0 0

منبع: Newsfile Corp خبرگزاری

یک ماه پیش

سهام اهمیت متوسط

MONDAY DEADLINE: Berger Montague Advises ADMA Biologics, Inc. (ADMA) Investors to Inquire About a Securities Fraud Class Action by August 10, 2026

Philadelphia, Pennsylvania--(Newsfile Corp. - August 7, 2026) - National plaintiffs' law firm Berger Montague PC announces a class action lawsuit against ADMA Biologics, Inc. (NASDAQ: ADMA) ("ADMA" or the "Company") on behalf of investors who purchased or acquired ADMA common stock during the period from August 9, 2024 through March 25, 2026 (the "Class Period"). Investor Deadline: Investors who purchased or acquired ADMA securities during the Class Period may, no later than August 10, 2026, seek to be appointed as a lead plaintiff representative of the class.

نمادهای مرتبط 1

A ADMA ADMA

منبع: Newsfile Corp

0 0 0

منبع: Seeking Alpha خبرگزاری

یک ماه پیش

سهام اهمیت متوسط

TPG RE Finance Trust: We Continue To Find The Series C Preferred Shares Attractive

TPG Real Estate Finance Trust (TRTX) Series C Preferred (TRTX.PR.C) remains a Buy, supported by robust Q2 2026 financials and prudent portfolio management. TRTX has reduced office exposure to 4.3% and shifted toward multifamily and industrial assets, mitigating sector risk. Leverage increased to 3.3x, balanced by conservative underwriting and a capital structure reset with long-term, non-mark-to-market debt.

نمادهای مرتبط 1

T TPG TPG

منبع: Seeking Alpha